"Immunocytochemistry experiments conducted on EGFRvIIIR cells revealed intense co-localization of PDK1 and EGFRvIII suggesting that PDK1 function is especially relevant for targeting the EGFRvIIIR-dependent GBMs."
"Mouse GBM xenografts tumor cells exhibited heterogeneous labeling of PDK1/EGFRvIII, with positive areas of staining detected alongside negative ones and the DCA treated tumors showed with very low PDK1/EGFRvIII (Figure 6C). Survival curves plotted revealed that DCA treatment increased the survival rate by more than 5 weeks in EGFRvIII treated mice and 3 weeks in EGFRvIIIR treated mice."
Note that this study is referring to PDK1, as in pyruvate dehydrogenase kinase 1, a known target to DCA, not to be confused with PDK1 (gene name: PDPK1) as in phosphoinositide-dependent kinase 1, a kinase that phosphorylates AKT as part of the PI3K/Akt pathway.
ReplyDeleteStephen, I'm so sorry for hijacking this thread too, but I'm rather desperate. Is there any boswellia serrata tablet that can be crushed? Or a capsule that can be opened up so its contents dissolve in water? I've only come across soft gel capsules which can't be broken up. I can't find any syrup either.
ReplyDeleteI reposted this for you as a separate post.
Delete